U.S. Hereditary Cancer Testing Market Size & Outlook
Related Markets
U.S. hereditary cancer testing market highlights
- The U.S. hereditary cancer testing market generated a revenue of USD 1,929.3 million in 2024 and is expected to reach USD 5,761.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 13.3% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating cancer in 2024.
- Breast Cancer is the most lucrative cancer segment registering the fastest growth during the forecast period.
Hereditary cancer testing market data book summary
| Market revenue in 2024 | USD 1,929.3 million |
| Market revenue in 2033 | USD 5,761.1 million |
| Growth rate | 13.3% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Breast Cancer |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer |
| Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Bio-Rad Laboratories Inc, CSL Ltd, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Abbott Laboratories, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Illumina Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 41.3% of the global hereditary cancer testing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. hereditary cancer testing market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 609.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Cancer Testing Market Scope
Hereditary Cancer Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Invitae Corp | View profile | 1700 | 1400 16th Street, San Francisco, CA, United States, 94103 | https://www.invitae.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
U.S. hereditary cancer testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary cancer testing market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 13.75% in 2024. Horizon Databook has segmented the U.S. hereditary cancer testing market based on lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to U.S. hereditary cancer testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. hereditary cancer testing market databook
-
Our clientele includes a mix of hereditary cancer testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hereditary cancer testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. hereditary cancer testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. hereditary cancer testing market size, by cancer, 2021-2033 (US$M)
U.S. Hereditary Cancer Testing Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
